The impact of REStrictive versUs LIberaL Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture

NEWSLETTER
14 July 2022 Issue 1

THANK YOU FOR YOUR CONTINUED SUPPORT!

Welcome to the **first RESULT-HIP newsletter**! Time is flying by and we want to thank you for your support and efforts. Firstly, some practical notes…

- We will be sending out welcome packs to sites within the Investigator Site File, so keep an eye out for the **promotional goodies** - see photo on the right!
- When discussing opening new sites, we are keen to meet with the **blood bank teams** and open the lines of communication between study teams and their blood bank – **identify** your contacts now.

Site Map

Green – Open
Orange – SIV completed
Blue – SIV pending

Recruitment

- The current number of participants recruited to 13 July stands at **7.**
- Recruitment began on 10th June 2022 and we now have **3 sites open** to recruitment, a further **1** who has had their SIV and will open imminently and **2** with SIVs pending - A very warm welcome to all!
- As we are aiming to open **10** sites for the pilot phase, we are currently seeking sites with the capacity to open in the coming months. If YOUR site has the scope to recruit up to **5 participants a month**, we want to hear from you.

Site	Total Recruited	No. recruited in June	No. recruited in July
Edinburgh	4	2	2
Rotherham	1	1	0
Durham	2	N/A	2
TOTAL	7	3	4

FUNDED BY
NIHR | National Institute for Health Research

This study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (16/93/01). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The impact of REStrictive versUs LIberaL Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture

NEWSLETTER
14 July 2022 Issue 1

Co-enrolment Update

Co-enrolment to RESULT-HIP has not yet been defined.

Please let us know of any other studies you would like to be considered for co-enrolment and we will confirm the suitability in discussion with our Trial Management Group.

Reminders

- Please enter your **screening logs** on to the database weekly.
- **Data queries** will be sent out to sites at the start of every month- please complete these as promptly as you can.
- If you have any **photos** that we can use in future newsletters, please do send them to us!

Contact Information

Study Mailbox : RESULTHip.trial@ed.ac.uk

Chief Investigator:
Prof. Michael Gillies Michael.Gillies@ed.ac.uk

Lead Research Nurse
Sophie Birch, 0131 242 3164,
Sophie.Birch@nhslothian.scot.nhs.uk

Trial Manager:
Gayle Beveridge, 0131 651 9906
gayle.beveridge@ed.ac.uk

Assistant Trial Manager:
Stephanie O'Donovan, 0131 651 9937,
Stephanie.O'Donovan@ed.ac.uk

Website: https://edin.ac/result-hip

ECTU
Edinburgh Clinical Trials Unit

FAQs - The ECTU team have compiled a list of FAQs and will continue to update them as other common queries are raised.

Q: How does the Day 3 (2-5) data collection time point work?
A: We entered this window to allow for some flexibility for teams who do not have cover over weekends. Day 3 data can be collected any time between Day 2 and Day 5, once 24 hours has passed since Day 1 data collection. The eCRF allows for dates of individual tests and interventions to be captured.

Q: If the Baseline troponin sample is missed, do I still collect further samples on Day 1 and Day 3 (2-5)?
A: Yes, if any test or reading is missed per the outline in the protocol, please continue to gather further samples wherever possible. Partial data is preferred to none at all, as this can still allow us to analyse the results for the primary and secondary outcomes.

Q: If a potential participant is receiving palliative care, are they eligible to be enrolled?
A: Yes. Only those participants not expected to survive >48 hours are ineligible. If someone is receiving palliative care over several months they may still be eligible. Please discuss appropriateness with the clinical team at your site prior to approaching the participant.

For England, Wales and N. Ireland only:
Q: If a potential participant's personal consultee has not been available to provide consent, should nominated consultee (professional) be sought instead?
A: Yes, if efforts have been made to contact a participant's family members, but they cannot visit the hospital for whatever reason, it may be more pragmatic to obtain professional consent from the clinical team. Where nominated consultee consent is used, we would encourage sites to continue to seek consent from family or the participant themselves if they regain consent. Nominated consultee consent allows for timeliness in randomising a participant and ensuring they can receive any transfusions required in a timely manner.